Double Medical(SZ:002901) Sou Hu Cai Jing·2025-10-31 13:24Core Viewpoint - The stock of Dabo Medical (002901) has shown a slight increase of 1.38% on October 31, 2025, closing at 50.04 yuan, with notable fluctuations in capital flow and strong financial performance in recent quarters [1][3]. Financial Performance - For the first three quarters of 2025, Dabo Medical reported a main revenue of 1.876 billion yuan, a year-on-year increase of 22.69% [3]. - The net profit attributable to shareholders reached 425 million yuan, up 77.03% year-on-year [3]. - The third quarter alone saw a main revenue of 666 million yuan, reflecting a 17.82% increase year-on-year, and a net profit of 180 million yuan, which is a 77.49% increase year-on-year [3]. Market Position - Dabo Medical's total market capitalization stands at 20.718 billion yuan, significantly higher than the industry average of 11.561 billion yuan, ranking 12th in the industry [3]. - The company has a gross margin of 71.23%, which is above the industry average of 51.22%, ranking 16th in the industry [3]. - The return on equity (ROE) is reported at 12.83%, substantially higher than the industry average of 0.15%, ranking 7th in the industry [3]. Capital Flow Analysis - On October 31, 2025, the net outflow of main funds was 146,400 yuan, accounting for 0.06% of the total transaction amount, while retail investors experienced a net outflow of 1.239 million yuan, representing 5.43% of the total transaction amount [1][2]. - Over the past five days, the stock has seen varying capital flows, with significant retail and speculative fund movements impacting the overall trading dynamics [2].